Allergan Details Revenue Expectations From Newly Acquired Inamed
This article was originally published in The Gray Sheet
Executive Summary
Allergan expects its recently completed acquisition of Inamed to add $355 mil. to $395 mil. in sales revenue this year
You may also be interested in...
Broad Coverage For Lap-Band Helps Grow Allergan’s Obesity Sales
CMS' decision to cover Allergan's Lap-Band laparoscopic adjustable gastric band for Medicare beneficiaries last February helped spark a 33% revenue jump for Allergan's obesity intervention business in 2006
Broad Coverage For Lap-Band Helps Grow Allergan’s Obesity Sales
CMS' decision to cover Allergan's Lap-Band laparoscopic adjustable gastric band for Medicare beneficiaries last February helped spark a 33% revenue jump for Allergan's obesity intervention business in 2006
Allergan builds obesity treatment portfolio
Allergan will pursue FDA approval of EndoArt's EasyBand remote-controlled gastric banding system for treatment of morbid obesity after acquiring the Swiss company for $97 million, the firm announces Feb. 22. The "next-generation" implant, intended for placement around the upper stomach, allows telemetric adjustment via an external controller to fit each patient's individual weight loss needs, the company says. Approved in Europe in mid-2006, EasyBand complements Allergan's Lap-Band adjustable gastric banding system. Allergan gained Lap-Band - currently the only adjustable implant for individualized weight loss approved in the United States - in its $3.2 billion purchase of Inamed last year (1"The Gray Sheet" April 3, 2006, p. 6). Allergan also offers its nonsurgical BIB BioEnterics intragastric balloon for obesity treatment outside the United States...